Non-Small Cell Carcinoma — Trials

Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,752
Recruiting: 926
Ph III recruiting: 138
Growth YoY: +2.3%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,046)

clinicaltrialsPublishedShowing 301–350 of 6,757 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02129699	Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR)	terminated	Phase 3	595	ETOP IBCSG Partners FoundationNETWORK	11	Sep 8, 2026	clinicaltrials
NCT04092283	Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer	active not recruiting	Phase 3	660	National Cancer Institute (NCI)NIH